Impact of early adalimumab (anti-TNF) therapy on job loss in early rheumatoid arthritis. Comment on the PROWD study.

Abstract

First double blind study analyzing as primary outcome decrease of work disability after application of early anti TNF therapy in rheumatoid arthritis.

Keywords

• rheumatoid arthritis
• anti-TNF therapy
• work disability